<![CDATA[Introduction: The worst gynecologic malignancy and the fifth-leading cause of cancer-related death in women worldwide is ovarian cancer. New therapeutic agents that are more effective and less likely to cause adverse reactions are urgently needed. Although flavonoids are primarily focused on their cytotoxic anticancer activity, they may also inhibit cell migration and invasion, affect cell cycle progression or induce apoptosis in specific tumor cells. This change may be related to flavonoids and ovarian cancer. That will be discussed in this study regarding the effects of flavonoid intakes on menopausal women to prevent ovarian cancer. Methods: Systematic searches were conducted using Google Scholar, Science Direct, PubMed, DOAJ (Directory of Open Access Journals), Cochrane, and Wiley. PRISMA 2020 rules are used to filter acquired articles. Studies examining the effects of flavonoids on ovarian cancer prevention considered for evaluation. Odds ratios and 95% confidence intervals (CIs) for random-effects meta-analyses were presented. Results: It was discovered that there is a correlation between flavonoids and the incidence of ovarian cancer during menopause among five studies that satisfied the requirements for inclusion in this article (n = 3886). The treatment group given flavonoids to reduce the incidence of apoptosis in ovarian granulosa cells in menopausal rats found that flavonoids reduced ovarian granulosa cell by 0.42 times compared with the placebo group (95% CI, OR=0.42 [0.18, 0.95]; P=0.04). Similarly, an isoflavone diet in menopausal women results in 0.89 times reduction in the risk of ovarian cancer compared with the group that does not follow an isoflavone diet, with OR=0.89 (CI 95%, 0.78, 1.02; P=0.08). When the five studies compared dietary isoflavones with flavonoid derivatives for ovarian cancer incidence, they showed a 0.87 times reduction in ovarian cancer incidence with dietary isoflavones (OR=0.87; CI 95%, 0.77, 0.99; P=0.04). Conclusion: In this meta-analysis, the efficacy of flavonoids compared to placebo can be considered as a preventive measure against ovarian cancer in menopause.]]>
